Trial Profile
An Open-Label Study of the Haemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Haemophilia A Patients With an Inhibitor to Human FVIII
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Octagen
- 17 Jun 2014 New trial record
- 03 Oct 2007